Position in MRK
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$1,696,200
+$114,267 QoQ
Shares Held
13,200
+0.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
1.42%
of 13F equity value
Holder Rank
#1,708
of 3,769 holders
Holding Since
Jun 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Davis Investment Partners, LLC holds $18,299,258 across 10 Drug Manufacturers - General names. MRK ranks #3 (9.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
29,096 | $7,389,511 | |
| 2 | ABBV |
AbbVie Inc.
|
10,900 | $2,742,876 | |
| 3 | MRK |
Merck & Co., Inc.
This page
|
13,200 | $1,696,200 | |
| 4 | AMGN |
Amgen Inc
|
4,600 | $1,665,752 | |
| 5 | LLY |
ELI LILLY & Co
|
1,243 | $1,490,891 | |
| 6 | NVS |
Novartis AG
|
5,658 | $886,721 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
15,381 | $886,253 | |
| 8 | BIIB |
Biogen Inc.
|
3,184 | $687,935 |
All Filings in MRK
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,696,200 | 13,200 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $1,581,933 | 13,151 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,682,581 | 15,985 | Shares | Sole | 2026-01-06 | |
| 2025-09-30 | $774,170 | 9,224 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $793,579 | 10,025 | Shares | Sole | 2025-07-08 | |
| 2025-03-31 | $657,761 | 7,328 | Shares | Sole | 2025-04-15 | |
| 2024-06-30 | $249,333 | 2,014 | Shares | Sole | 2024-07-18 | |
| 2024-03-31 | $245,163 | 1,858 | Shares | Sole | 2024-04-15 | |
| 2023-12-31 | $215,641 | 1,978 | Shares | Sole | 2024-01-12 | |
| 2023-09-30 | $203,635 | 1,978 | Shares | Sole | 2023-10-10 | |
| 2023-06-30 | $389,787 | 3,378 | Shares | Sole | 2023-08-01 | |
| No filing history on record for this holder in this stock. | ||||||